Abstract: -It seems odd to state that rounding to 2 decimal places results in the models being equivalent. Just keep 3 decimal places and remove this extraneous comment. I agree that it seems that there's not much difference between the models, and this needs to be discussed in the Discussion. -Need to mention whether cross-validation or external validation was performed.
-Need to give c-statistic for SVM. -Need to mention in Study Design that you also tested and updated existing measures (e.g., Charlson). -Need to interpret the meaning of the c-statistic in practical/clinical terms. What does it mean, in terms of the probability that an individual patient's outcome will be correctly "categorized"? Background -First paragraph needs references to the literature. -The Introduction seems very disjointed, there is very little holding various sentences together. E.g., the first paragraph is just a list of definitions, the second paragraph is a collection of sentences about mortality that seem unrelated and do not build a cogent argument or motivation for the study, the third paragraph seems irrelevant to the topic at hand. -The fourth paragraph of the introduction seems the most relevant, although I don't understand point (3), it includes a lot of jargon (p. 5 line 24).
Methods -The description of the data set is confusing. How were the HMO and state buy-in indicators used in this analysis (p. 7, line 41)? -What is meant by "explanatory/target" variable (p. 7, line 52)? Do the authors mean the "outcome" or "dependent" variable? This sentence in general is confusingly worded. I think the authors are trying to say that the predictor variables were derived from the 2014 data, in order to be temporally antecedent to the outcome variable, which was derived from 2015-2016 data.
-I don't understand the motivation for excluding people with hospice claims, p. 8 line 50. This represents the projection of ex ante hypotheses on the part of the authors, which runs counter to the typical approach for predictive models, which is to include all plausible predictors.
-If anything, I think it would make more sense to exclude people who may be very different from the general > 65yr-old Medicare population, e.g. younger people with disabilities. They probably have very different predictors of mortality than the more homogeneous older population, and shouldn't just be lumped in because they happen to have the same type of insurance coverage.
-The list of variables on p.9 should go in a table, in which one column provides explanation for some of those that are not selfexplanatory, e.g., "Clinical Classification Software indicators." Similarly, I assume the number in parentheses is the number of terms: but why are there 20 age and gender categories? Does it make sense to include both the Charlson indicators and the Charlson score, if the score is simply a linear combination of the indicators? -Why did the authors select these particular statistical models from among the many more that are available (p. 10, line 8).
-Much more detail is needed on the models (p. 10, lines 21-39). This paragraph seems like a long list without explanation of each of the steps. E.g., how was stepwise selection done? Why would you want to reduce the number of variables via stepwise and Lasso models? (E.g., to make it usable in a clinical setting?) What does it means for the SVM to be "estimable" (p. 10, line 37)? -"In all cases, both the training…" This sentence is confusingly worded and doesn't accurately capture the purpose of crossvalidation (p. 10, line 48).
-The authors present the results of several other analyses in the Results section, but these are not described in the Methods. Please describe all the analyses that you do. -How were the Charlson conditions identified? Are these done using ICD-9/10 codes? -Need a statement regarding ethical approval, or that none was needed.
Results -"The medical service utilization rates…" This sentence seems unnecessary, especially if the authors aren't directly comparing these numbers to actual statistics to demonstrate the representative nature of the data set (p. 11, line 30). -I don't understand what the "25%" is referring to when explaining the gender split (p. 11, line 39).
-"One criticism of a logistic regression…" I don't understand this paragraph, and it seems like it should go in the Discussion (p. 12, line 41-53).
-The Results section should indicate which variables were retained by the stepwise and Lasso models and provide the coefficients in an online Supplemental Table, so that the model can actually be used by others.
-If the authors intend for this to be clinically relevant, than 154 retained variables is far too many. Do you expect physicians to calculate this at bedside, or hospital administrators to run it on claims data? Intention needs to be clearer. If you want clinicians to use this at bedside, than you need to force the model to select fewer coefficients.
-"This stepwise regression model…" I don't understand what the authors are doing here, and in any case the analysis needs to be described in the Methods and only the Results presented here.
-The list of conditional statements describing the construction of the weights on p. 14 should be in a 
Discussion
-Additional results are presented in the first paragraph of the Discussion. These should be moved to the Results. A Discussion section needs to start with a big picture summary of the study results, before drilling down to the details. In general, it seems that all of these models don't do a whole lot better than what we already have, right? -"This study found that people who were in an HMO…" It is not appropriate to interpret the individual coefficients in these models as causal, since this is a predictive model, there is likely to be confounding by unobserved characteristics, and many predictors are likely to be correlated. -The Discussion is very short, and there is virtually no contextualization of the results in the broader literature of predictive models for mortality. -It seems odd that 6 conditions are now assigned a weight of 0 in the authors' updated Charlson scoring. This is an example of something the authors should discuss in this section.
-How should we interpret the fact that the Schneeweiss and updated Charlson weights in Figure 2 
GENERAL COMMENTS
This provocative manuscript uses the 5% CMS limited dataset to evaluate the accuracy for the prediction of death in patients that are not hospitalized (community dwelling). Nine separate risk models were used with patient variables derived from the 2014 administrative records of the 2.7 million surviving patients, and these models were applied to predict deaths in a 15-month interval beginning with the start of calendar year 2015. The accuracy of the evaluated models was assessed with c-statistics. The final results demonstrated comparability of four models that used linear regression with all variables, stepwise linear regression, linear regression using the Lasso technique for variable selection, and use of the neural network. While an 80% accuracy rate in predicting between patient that lived versus those that died for the study period is good performance of the models, it misses the mark for supporting clinical decisions about which patients should be moved to supportive, palliative, or hospice care. Other interesting observations was that the mortality rate of hospice patients was only 64% when in theory it should have approached 100% for the study period as the authors have pointed out. Another interesting feature is that the death rate was increased in the Medicare Advantage program which begs the question of whether necessary care was actually withheld in the interest of better economic margins by the insurer. The authors have failed to address this specific issue of why the very popular Advantage program in the U.S. has poorer results. In summary I favor publication of the manuscript because the comparative statistical methods used are very useful for analytic investigators that are trying to assess which method is best. The additional observations about hospice decisions and the outcomes of Medicare Advantage patients needs to be publicly aired for further debate in the published literature.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Summary: The purpose of this study was to use two years of Medicare claims data to develop an algorithm that best predicted 15-month mortality. While this is an interesting question and uses a large nationally representative dataset, the manuscript is not well written. It would benefit from a substantial revision to be more consistent with standard academic writing, with a focus also on the grammar and wording. There is very little contextualization within the existing literature in both the Introduction and Discussion, the Methods are poorly described, and the Results don't provide a complete picture of what was found.
Abstract:
• It seems odd to state that rounding to 2 decimal places results in the models being equivalent. Just keep 3 decimal places and remove this extraneous comment. I agree that it seems that there's not much difference between the models, and this needs to be discussed in the Discussion.
o
This sentence has been removed. The similarity of the models is discussed in the Discussion section.
• Need to mention whether cross-validation or external validation was performed.
o The method of cross validation is now mentioned in the abstract.
• Need to give c-statistic for SVM. o This has been added along with the c-statistic for the Elixhouser condition model.
• Need to mention in Study Design that you also tested and updated existing measures (e.g.,
This has been mentioned in the Study Design.
• Need to interpret the meaning of the c-statistic in practical/clinical terms. What does it mean, in terms of the probability that an individual patient's outcome will be correctly "categorized"? o This has been added to the methods section on statistical methods with an additional reference.
Background
• First paragraph needs references to the literature. o References have been added to the first paragraph.
• The Introduction seems very disjointed, there is very little holding various sentences together. E.g., the first paragraph is just a list of definitions, the second paragraph is a collection of sentences about mortality that seem unrelated and do not build a cogent argument or motivation for the study, the third paragraph seems irrelevant to the topic at hand. o The introduction has been revised. Clinical context of mortality indicators and utility to clinicians has been added.
•
The fourth paragraph of the introduction seems the most relevant, although I don't understand point (3), it includes a lot of jargon (p. 5 line 24).
o
The potential utility of the mortality prediction model (translated in to a last-year-of-life indicator) for clinicians has been separated from the potential utility for payers in the evaluation of premium risk-adjustment.
Methods

•
The description of the data set is confusing. How were the HMO and state buy-in indicators used in this analysis (p. 7, line 41)?
The description of the data has been revised. The HMO and state buy-in indicator description has been revised and moved to the section on explanatory variables since both were used as explanatory variables in the predictive models.
• What is meant by "explanatory/target" variable (p. 7, line 52)? Do the authors mean the "outcome" or "dependent" variable? This sentence in general is confusingly worded. I think the authors are trying to say that the predictor variables were derived from the 2014 data, in order to be temporally antecedent to the outcome variable, which was derived from 2015-2016 data.
The machine learning literature uses "target" variable to mean dependent or outcome variable and uses "feature" to mean explanatory or dependent variables. The manuscript has been revised to use the language from statistics and epidemiology and to consistently use outcome variable and explanatory variables.
Yes, we were trying to say that the explanatory variables were derived from the 2014 data, in order to be temporally antecedent to the outcome variable, which was derived from 2015-2016 data. The manuscript has been revised to say this.
• I don't understand the motivation for excluding people with hospice claims, p. 8 line 50. This represents the projection of ex ante hypotheses on the part of the authors, which runs counter to the typical approach for predictive models, which is to include all plausible predictors. o
The motivation and objective for this mortality risk prediction model is to assist clinicians by providing a mortality risk indicator that identifies those patients that are most likely to benefit from the initiation of advance care planning and transition to palliative and end-of-life care consistent with each patient's wishes. Referral to hospice (as indicated by 1 or more hospice claims) is an indicator that clinicians have already identified that death in the next six months is likely, and therefore inclusion of those beneficiaries in the model does not provide any new information to providers.
• If anything, I think it would make more sense to exclude people who may be very different from the general > 65yr-old Medicare population, e.g. younger people with disabilities. They probably have very different predictors of mortality than the more homogeneous older population, and shouldn't just be lumped in because they happen to have the same type of insurance coverage. o
The manuscript in the sample size section has been revised to explicitly state the motivation, "This study included the entire five percent sample of the U.S. Medicare population, which increases its generalizability…The motivation for including all CMS beneficiaries is to develop a predictive model from all CMS community dwelling beneficiaries rather than restrict to a certain state, age, or demographic characteristic to enhance the models generalizability."
The list of variables on p.9 should go in a table, in which one column provides explanation for some of those that are not self-explanatory, e.g., "Clinical Classification Software indicators." Similarly, I assume the number in parentheses is the number of terms: but why are there 20 age and gender categories? Does it make sense to include both the Charlson indicators and the Charlson score, if the score is simply a linear combination of the indicators? o
The list of explanatory variables has been put in a table with a column providing an explanation for those that are not self-explanatory.
Another column shows the number of variables in each category which was previously the number in parentheses.
The 20 age and gender categories are explained in the new table as 10 age categories for each gender.
Although the Charlson score is a linear combination of the Charlson indicators, including both allows for the machine learning algorithms to pick which variables to use when making predictions. Specifically, the LASSO and stepwise techniques use an algorithm to pick variables and we did not want to limit this selection algorithm.
• Why did the authors select these particular statistical models from among the many more that are available (p. 10, line 8).
o Nine different models were estimated. This has been revised to be clearer in the number and types of models estimated. Models not chosen include the Naïve Bayes estimator which was not chosen given the often-faulty assumption of equally important and independent explanatory variables required for this model. The other broad family of models is the decision tree. This type of model was not chosen given the reliance on axis-parallel splits.
• Much more detail is needed on the models (p. 10, lines 21-39). This paragraph seems like a long list without explanation of each of the steps. E.g., how was stepwise selection done? Why would you want to reduce the number of variables via stepwise and Lasso models? (E.g., to make it usable in a clinical setting?) What does it means for the SVM to be "estimable" (p. 10, line 37)? o This has been revised to include more detail on the models including how stepwise selection was done and why reducing the number of variables via stepwise and LASSO models was desired. In addition, the SVM model was clarified in terms of its estimation.
• "In all cases, both the training…" This sentence is confusingly worded and doesn't accurately capture the purpose of cross-validation (p. 10, line 48). o This has been removed to avoid confusion and redundancy since the sample size section explains the cross validation and its purpose, "Second, the 2.7 million beneficiaries were randomly split into a training and a validation dataset with 1.35 million beneficiaries in each. This method of simple cross validation, or hold-out cross validation, was chosen given the abundance of data. The validation dataset was used to ensure that overfitting did not occur. Overfitting occurs when a model with enough complexity predicts very well in the training dataset but does not predict well in a validation dataset. Overfitting would generate spurious relationships that are not generalizable to another dataset. It is the validation dataset that checks that the estimated model is generalizable and not spurious."
• The authors present the results of several other analyses in the Results section, but these are not described in the Methods. Please describe all the analyses that you do.
The method for updating the Charlson scores and calculating the average Charlson score by risk bands has been moved to the Methods section under a new section heading named, "Charlson Weights".
• How were the Charlson conditions identified? Are these done using ICD-9/10 codes? o This has been added to Table 1 which describes the explanator variables. Both ICD9 and ICD10 codes were used.
• Need a statement regarding ethical approval, or that none was needed.
o The data section has been edited to include the following, "The Centers for Medicare & Medicaid Services (CMS) makes Limited Data Set (LDS) files available to researchers. As such no ethical board approval was needed."
Results
•
"The medical service utilization rates…" This sentence seems unnecessary, especially if the authors aren't directly comparing these numbers to actual statistics to demonstrate the representative nature of the data set (p. 11, line 30) . o This sentence has been removed.
• I don't understand what the "25%" is referring to when explaining the gender split (p. 11, line 39). o This has been revised to read, "Not surprising, given higher female longevity compared to males, there are more females than males, represented by roughly fifty-four percent female in each dataset".
• "One criticism of a logistic regression…" I don't understand this paragraph, and it seems like it should go in the Discussion (p. 12, .
o This paragraph has been revised to be clearer and moved to the Discussion section.
• The Results section should indicate which variables were retained by the stepwise and Lasso models and provide the coefficients in an online Supplemental Table, so that the model can actually be used by others. o An online supplement was created to list the lists the odds ratios for the 154 variables retained in the stepwise model. The LASSO model retained 401 variables and is thus close to the full model of 568 variables and not included in the supplement.
• If the authors intend for this to be clinically relevant, than 154 retained variables is far too many. Do you expect physicians to calculate this at bedside, or hospital administrators to run it on claims data? Intention needs to be clearer. If you want clinicians to use this at bedside, than you need to force the model to select fewer coefficients.
The introduction and discussion sections have been revised to describe the inclusion of a last-year-of-life indicator that could be appended in patient medical records.
• "This stepwise regression model…" I don't understand what the authors are doing here, and in any case the analysis needs to be described in the Methods and only the Results presented here.
o
The following has been added to the Methods section, "In addition, decile risk bands of the predicted probability of death were calculated. The first risk band are those people who have a predicted probability between 0 and 0.1. The second risk band are those people who have a predicted probability between 0.1 and 0.2, etc. The stepwise predictive model was used to derive these predicted probabilities using the validation dataset and used to compare actual death rates by risk band."
Only the results of this comparison is now in the results section.
The list of conditional statements describing the construction of the weights on p. 14 should be in a table. o This is now in a table.
• "…but at a lower level." I don't understand what the authors mean by this (p. 15, line 17) . The typical range and mean would depend on the population studied. For this CMS population, the mean is included in the descriptive statistics table.
• Why would we expect more hospice claims to mean more death? If anything, it means that the person has somehow survived longer and accumulated another claim, i.e. survivorship bias.
The key clinical eligibility criteria for transition into hospice is a physician's assessment that death is probable in the ensuing 6 months. Hence our assumption that higher death rates would correlate with hospice claims.
Discussion
• Additional results are presented in the first paragraph of the Discussion. These should be moved to the Results. A Discussion section needs to start with a big picture summary of the study results, before drilling down to the details. In general, it seems that all of these models don't do a whole lot better than what we already have, right? o
The additional results presented in the first paragraph of the Discussion have been moved to the results section.
o Big picture summary now starts the discussion with a discussion of factors to consider when evaluating predictive model algorithms and contextualization of the results in the broader literature of predictive models for mortality. o
Although these predictive models did not produce significantly different c-statistics from previously developed models these new models do provide much greater clinical utility based on generalizability across geographic areas, the full spectrum of disease and full range of health statuses. Generalizability is a key requirement for the application of predictive analytics indicators toward enhanced clinical judgements of which patients are likely to benefit from the initiation of advanced care planning and subsequent transition to palliative and hospice care.
• "This study found that people who were in an HMO…" It is not appropriate to interpret the individual coefficients in these models as causal, since this is a predictive model, there is likely to be confounding by unobserved characteristics, and many predictors are likely to be correlated.
The discussion of a correlation between death rate and HMO enrollment has been revised.
• The Discussion is very short, and there is virtually no contextualization of the results in the broader literature of predictive models for mortality.
o
The discussion has been lengthened and given context of the results in the broader literature of predictive models for mortality including a discussion of factors to consider when evaluating predictive model algorithms and contextualization of the results in the broader literature of predictive models for mortality.
• It seems odd that 6 conditions are now assigned a weight of 0 in the authors' updated Charlson scoring. This is an example of something the authors should discuss in this section. o
This has been explained in the discussion.
• How should we interpret the fact that the Schneeweiss and updated Charlson weights in Figure 2 are essentially parallel? So the current model doesn't do much better? o
The model does not produce a significantly higher c-statistic, however, it does provide much greater clinical utility based on generalizability across geographic areas, the full spectrum of disease and full range of health status. This reflected only people age 60 and over. This has been revised to show the percentages by gender which add up to 100%. In addition, the percent of total people over the age of 60 has been added.
• Please give the average age of the sample in Table 1. o This has been added to Table 1. • Y axis of Figure 2 should be labeled. o This has been added.
• Can the authors also graph the scores against actual mortality, as they did for • Figure 3 would be more helpful with error bars, to determine whether these are statistically significantly different from one another. o This figure has been edited to include 95% confidence error bars.
Reviewer: 2
This provocative manuscript uses the 5% CMS limited dataset to evaluate the accuracy for the prediction of death in patients that are not hospitalized (community dwelling). Nine separate risk models were used with patient variables derived from the 2014 administrative records of the 2.7 million surviving patients, and these models were applied to predict deaths in a 15-month interval beginning with the start of calendar year 2015. The accuracy of the evaluated models was assessed with c-statistics. The final results demonstrated comparability of four models that used linear regression with all variables, stepwise linear regression, linear regression using the Lasso technique for variable selection, and use of the neural network.
• While an 80% accuracy rate in predicting between patient that lived versus those that died for the study period is good performance of the models, it misses the mark for supporting clinical decisions about which patients should be moved to supportive, palliative, or hospice care. o
The motivation and objective for this mortality risk prediction model is to assist clinicians by providing a mortality risk indicator that identifies those patients that are most likely to benefit from the initiation of advance care planning and transition to palliative and end-of-life care consistent with each patient's wishes. The introduction and discussion sections have been revised to describe the inclusion of a last-year-of-life indicator that could be appended in patient medical records. o
The model does not produce a significantly higher c-statistic, however, it does provide much greater clinical utility based on generalizability across geographic areas, the full spectrum of disease and full range of health status.
• Other interesting observations was that the mortality rate of hospice patients was only 64% when in theory it should have approached 100% for the study period as the authors have pointed out. o A discussion of the challenges and inherent inaccuracy of predicting time until death based on clinical judgement alone on has been added.
• Another interesting feature is that the death rate was increased in the Medicare Advantage program which begs the question of whether necessary care was actually withheld in the interest of better economic margins by the insurer. The authors have failed to address this specific issue of why the very popular Advantage program in the U.S. has poorer results. o A revised discussion of the possible interpretations of the higher death rate among MA members has been added.
In summary I favor publication of the manuscript because the comparative statistical methods used are very useful for analytic investigators that are trying to assess which method is best. The additional observations about hospice decisions and the outcomes of Medicare Advantage patient's needs to be publicly aired for further debate in the published literature. 
GENERAL COMMENTS
The author has addressed the concerns of the initial review.
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GENERAL COMMENTS
This is a very nice paper, but it doesn't acknowledge the wealth of studies that have been performed on mortality prediction in the biomedical informatics and the computer science community. The paper is well motivated and a good study; however, I feel it would be far more interesting and relevant if they were to do a broader review of existing methods and integrate some of these approaches into the study design. Right now, it's strictly from the perspective of a traditional epidemiologist/health services researcher and there has been innovation in these types of predictive modeling problems outside of these domains.
VERSION 2 -AUTHOR RESPONSE
Reviewer: 3 This is a very nice paper, but it doesn't acknowledge the wealth of studies that have been performed on mortality prediction in the biomedical informatics and the computer science community. The paper is well motivated and a good study; however, I feel it would be far more interesting and relevant if they were to do a broader review of existing methods and integrate some of these approaches into the study design. Right now, it's strictly from the perspective of a traditional epidemiologist/health services researcher and there has been innovation in these types of predictive modeling problems outside of these domains.
• This manuscript now has two additional methods have been integrated. Both a naïve Bayes and a decision tree with adaptive boosting model have been incorporated.
• Also, beyond the perspective of a traditional epidemiologist/health services researcher, a paragraph summarizing from an engineering and computer science perspective, has been added to acknowledge this perspective from journals and conferences in these disciplines.
